CAPITAL STOCK - Schedule of Summary of Stock Option Activity (Details) - Share-based Payment Arrangement, Option - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 28, 2025	Mar. 29, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	993,587
Options Outstanding, (in shares), Granted	221,999
Options Outstanding, (in shares), Exercised	(13,323)
Options Outstanding, (in shares), Forfeited	(93,535)
Options Outstanding, (in shares), Ending Balance	1,108,728	993,587
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 81.75
Weighted Average Exercise Price (in dollars per share), Granted	70.29
Weighted Average Exercise Price (in dollars per share), Exercised	57.10
Weighted Average Exercise Price (in dollars per share), Forfeited	92.30
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 78.87	$ 81.75
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	4 years 2 months 12 days	3 years 6 months
Aggregate Intrinsic Value, Balance	$ 6,580	$ 2,249
Options Outstanding, (in shares), Exercisable and End of Period	651,653
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 79.67
Weighted Average Remaining Life, Exercisable at End of Period	2 years 10 months 24 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 4,924
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	982,146
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 79.04
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years 6 months
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 6,180

HAEMONETICS CORP 10-Q